

**CURRICULUM VITAE
LANCE D. DWORKIN, M.D.**

Business Address: Rhode Island Hospital,
593 Eddy Street, Middle House 301
Providence, RI 02906
Business Telephone: 401-444-6844
Business Fax: 401-444-6849
E-mail Address: ldworkin@lifespan.org

EDUCATION

Undergraduate: Yale University, B.A. in Chemistry, 1971, Cum Laude
Medical School: University of Pennsylvania School of Medicine, 1975
Other Advanced Degrees: Brown University, M.A. Ad Eundum, 1994

POSTGRADUATE TRAINING

Residency: New York University and Bellevue Hospitals, New York, New York, Medical Resident, 1975-1978
New York University and Bellevue Hospitals, New York, New York, Chief Medical Resident, 1978-1979
Fellowship: Harvard Medical School and Peter Bent Brigham Hospital, Boston, Massachusetts, Clinical Fellow in Medicine and Nephrology, 1979-1981
Harvard Medical School and Peter Bent Brigham Hospital, Boston, Massachusetts, Research Fellow in Medicine and Nephrology, 1980-1982

POSTGRADUATE HONORS AND AWARDS

National Research Service Award, National Institutes of Health, 1980, 1981
New Investigator Award, National Institutes of Health, 1984-1987
Career Scientist Award, Irma T. Hirsch Trust, 1985-1990
Grant-In-Aid, American Heart Association, 1992, 1998
Specialist in Clinical Hypertension, American Society of Hypertension, 1999-present
Who's Who in America, 2000-present
Brown Medical School Dean's Teaching Excellence Award, Bio 301 Clerkship in Medicine, July, 2001
American Heart Association, Fellow of the Council on the Kidney in Cardiovascular Disease, F.A.H.A., November, 2003
American Society of Nephrology, Fellow of the ASN, September, 2004
Brown Medical School Dean's Teaching Excellence Award, Bio 281 Pathophysiology/Renal, June, 2003, 2004, 2005
Best Doctors of America, 2005, 2006, 2007
Honorary Professor, Jinling Hospital, Nanjing University School of Clinical Medicine, Nanjing, China, 2007-2010

MILITARY SERVICE N/A

PROFESSIONAL LICENSES AND BOARD CERTIFICATION

Rhode Island State License, 1993-present
New York State License, 1975-1979, 1982-1993
Massachusetts State License, 1979-1982
American Board of Internal Medicine, Board Certification in Internal Medicine, 1978
American Board of Internal Medicine, Board Certification in Nephrology, 1982

ACADEMIC APPOINTMENTS

Assistant Professor of Medicine, New York University Medical Center, 1982-1989
Associate Professor of Medicine, New York University Medical Center, 1989-1993
Associate Professor of Medicine, Brown Medical School, 1993-2000
Professor of Medicine, Brown Medical School, 2000-present
Vice Chairman of Medicine, Brown Medical School, 2006
Director, Division of Renal Diseases, Brown Medical School, 1993-present

HOSPITAL APPOINTMENTS

Assistant Attending in Medicine, Bellevue Hospital, New York, NY, 1982-1993
Attending Physician, Medical Service-Nephrology Section, Veterans Administration Hospital, New York, NY, 1982-1983
Director, Division of Renal Diseases, Rhode Island Hospital, Providence, RI, 1993-present
Director, Division of Renal Diseases, The Miriam Hospital, Providence, RI, 1995-present
Consulting Physician, Veterans Administration Medical Center, Providence, RI, 1996-present
Courtesy, Newport Hospital, Newport, RI, 2003-present
Courtesy, Memorial Hospital of RI, Pawtucket, RI, 2003-present
Courtesy, Landmark Medical Center, Woonsocket, RI, 2003-present
Courtesy, Our Lady of Fatima Hospital/St. Joseph's Health Services, North Providence, RI, 2003-2007

OTHER APPOINTMENTS

Medical Director, Artificial Kidney Centers of Rhode Island (East Providence, North Providence, Warwick, Woonsocket Outpatient Dialysis Centers, & Inpatient Dialysis Program), 2003-2006
Ad Hoc Reviewer, Pathology A Study Section, National Institutes of Health, 1989
Cardiorenal Research Study Committee, American Heart Association, 1990-1991
New York Society of Nephrology, President, 1991
National Kidney Foundation of New York/New Jersey Medical Advisory Board, 1992-1993
2nd, 3rd, and 4th International Symposium on ACE Inhibitors Program Committee
Membership on Editorial Board, American Journal of Kidney Disease, 1991-1996
Membership on Editorial Board, Hypertension, 1993-1996
Membership on Editorial Board, Clinical Nephrology, 1992-present
National Kidney Foundation of Massachusetts and Rhode Island Grant Study Section, 1993, 1995, 1997, 1998, 1999, Chairman, 2000

National Kidney Foundation of Massachusetts and Rhode Island Symposium Committee, Chairman, 1997
National Kidney Foundation Executive Committee of the Council on Hypertension, 1997-present
National Kidney Foundation of Massachusetts and Rhode Island Medical Advisory Board, 1997-present
Homer W. Smith Award Committee, American Heart Association, American Society of Nephrology, 1997-2001
American Society of Nephrology Government Relations Committee, 1998-2004
American Society of Nephrology Medical School Debt Reduction Committee, Chairman, 1999
National Institute of Health General Medicine B Study Section & Urology Special Emphasis Panel, 2000, 2001
Ad Hoc Reviewer, National Institute of Health, Kidney Dialysis, Monitoring and Therapeutics Review Study Section, August and October, 2006
American Society of Nephrology Ad-hoc Public Policy Priorities Working Group on Increasing RO1 grants for kidney disease research, Chairman, 2001
American Society of Nephrology, Policy and Public Affairs Committee, 2005-2006
American Society of Nephrology, Hypertension Advisory Group, 2005-present
Ad Hoc Reviewer for:
American Journal of Hypertension, 1986-present
American Journal of Kidney Diseases, 1984-present
American Journal of Physiology, 1989-present
Cancer, 2000-present
Cardiovascular Drugs and Therapy, 1988-present
European Journal of Pharmacology, 2000-present
Experimental Nephrology, 1994-present
Hypertension, 1984-present
Journal of Cellular Physiology, 1986-present
Journal of Clinical Investigation, 1986-present
Journal of Hypertension, 1990-present
Journal of Laboratory and Clinical Medicine, 1990-present
Journal of the American Society of Nephrology, 1993-present
Kidney International, 1982-present
Nephron, 1982-present
The New England Journal of Medicine, 1999-present
NKF-DOQI - Clinical Practice Guidelines or Nutrition in Renal Failure, 1999
Reviewer of Abstracts submitted to Annual Meetings:
American Federation for Clinical Research, 1986
International Society of Hypertension, 1984-1996
The American Society of Nephrology, 1984-present
The American Society of Nephrology, Hemodynamics, Hypertension and Vascular Regulations, Chairman, 2000
The American Heart Association, 2003
Section Editor
Current Opinion in Nephrology and Hypertension, *Circulation and Hemodynamics*: Lance Dworkin and Harald Sinclair Mackenzie, Vol. 9 No. 1, January, 2000

HOSPITAL COMMITTEES

Rhode Island Hospital Research Advisory Committee, 1993-1997
Rhode Island Hospital Animal Welfare Committee, 1993-1998
Rhode Island Hospital Council of Chiefs, 1994-1997
Rhode Island Hospital Clinical Advisory Group Search Committee, 1996-1997
Rhode Island Hospital Intern Advisor, 1993-present
Rhode Island Hospital and The Miriam Hospital Staff Planning Committees, 1996-2000
Rhode Island Hospital MICU Leadership Group, 1996-present
Rhode Island Hospital/University Medicine Foundation Finance Committee, 1998-present
Rhode Island Hospital/University Medicine Foundation Investment Committee, 1998-present
Rhode Island Hospital/University Medicine Foundation Human Resources Committee, 1998-present
Rhode Island Hospital CRC Advisory Committee, Chair, 2000-2002
Rhode Island Hospital DNA Committee (RDC), 2001-present
Rhode Island Hospital Website Committee, 2001-present
Rhode Island Hospital/University Medicine Foundation Building Steering Committee, 2003
Rhode Island Hospital/University Medicine Foundation Clinical Operations Strategic Planning Committee, 2006-present
Rhode Island Hospital/University Medicine Foundation Outsourcing Contracts Development Committee, 2006-present

UNIVERSITY COMMITTEES

New York University Medical Center Independent Study Committee, Chairman, 1991-1993
New York University Institution Animal Use and Care Committee, 1984-1993
New York University General Clinical Research Center Advisory Committee, 1989-1993
New York University Department of Medicine Internship Selection Committee, 1982-1993
New York University Animal Faculty Design Committee, 1992-1993
New York University Department of Medicine Internship Advisor, 1982-1993
New York University Nephrology Fellow Selection Committee, 1982-1993
New York University Faculty Mentor BA-MD program, 1990-1993
Brown University, Department of Medicine Integration Implementation Committee, 1998
Brown University, Department of Medicine Integration Finance Committee, 1998, Chairman
Brown University, Department of Medicine Endocrinology Search Committee, Chairman, 1999-2000
Brown University, Department of Medicine Cardiology Search Committee, 1999-present
Brown University, Department of Medicine Nephrology Search Committee (Clinical), Chairman, 1999, 2003
Brown University, Department of Medicine Nephrology Search Committee (Research), Chairman, 1999-present
Brown University, Department of Medicine Research Committee, 1998-present
Brown University Ad Hoc Committee on Medical Faculty Affairs, Chairman, 1997
Brown University Curriculum Committee, 1996-present
Brown University Faculty Executive Committee, 1997-1998
Brown University Basic Biology of Cells Assessment Committee, 1998
Brown University Biomedical Faculty Council Committee, 1999
Brown University Medical Residency Management Group, 1993-present

Brown University, Department of Medicine Promotions Committee, 2000-present
Brown University, Department of Medicine Promotions Guidelines Committee, (Chair), 2002-present
Brown University Committee on Medical Faculty Appointments, 2005-present
Brown University Committee on Clinical and Translational Science Awards, 2007

MEMBERSHIP IN SOCIETIES

American Association for Advancement of Sciences, 1996-present
American College of Physicians/American Society of Internal Medicine, Fellow, 2002-present
American Federation for Clinical Research, 1984-present
American Heart Association, Council on Hypertension, FAHA, 1988-present
American Society of Hypertension, 1986-present
American Society of Nephrology, FASN, 1982-present
Association of Professors of Medicine, 2006
International Society of Nephrology, 1988-present
National Kidney Foundation, 1994-present
New York Society of Nephrology, 1984-1993, President 1991
Renal Physicians Association, 1998-present

COMMUNITY/CHARITABLE ACTIVITIES

National Kidney Foundation of Massachusetts and Rhode Island Medical Advisory Board, 1997-present
National Kidney Foundation Rhode Island Kidney Early Evaluation Program, Medical Director, 2001-present
National Kidney Foundation Kidney Ball, Co-Chairman, 2001

ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS

Articles:

1. Van Buren CT, Dudrick SJ, **Dworkin LD**. Effects of intravenous essential L-amino acids and hypertonic dextrose on anephric beagle. *Surgical Forum*. 23:83, 1972.
2. **Dworkin LD**, Levine GM, Farber SJ, Spector MH. Small intestinal mass of the rat is partially determined by indirect effects of intraluminal nutrition. *Gastroenterology*. 71:626,1976.
3. Mehl SJ, Kaltman AJ, Kronzon J, **Dworkin LD**, Adams P, Spencer FC. Combined tricuspid and pulmonic stenosis. *J Thor Card Surg*. 74:55, 1977.
4. Hostetter TH, Pfeffer JM, Pfeffer MA, **Dworkin LD**, Braunwald E, Brenner BM. Cardiorenal hemodynamics and sodium excretion in rats with myocardial infarction. *Am J Physiol*. 245:H98, 1983.
5. **Dworkin LD**, Hostetter TH, Rennke HG, Brenner BM. Hemodynamic basis for glomerular injury in rats with desoxycorticosterone-salt hypertension. *J Clin Invest*. 73:1448, 1984.
6. **Dworkin LD**, Feiner HD. Glomerular injury in uninephrectomized spontaneously hypertensive rats: A consequence of glomerular capillary hypertension. *J Clin Invest*. 77:797, 1986.

7. **Dworkin LD**, Feiner HD, Randazzo J. Glomerular hypertension and injury in desoxycorticosterone-salt rats on antihypertensive therapy. *Kidney Int.* 31:718-724, 1987.
8. Alfino PA, Neugarten J, Schacht RG, **Dworkin LD**, Baldwin DS. Glomerular size-selective barrier dysfunction in nephrotoxic serum nephritis; amelioration by antihypertensive therapy. *Kidney Int.* 34:151-155, 1988.
9. **Dworkin LD**, Grosser M, Feiner HD, Ullian M, Parker M. The renal vascular effects of antihypertensive therapy in uninephrectomized spontaneously hypertensive rats. *Kidney Int.* 35:790-798, 1989.
10. **Dworkin LD**, Feiner HD, Parker M. Supplementing dietary calcium exacerbates glomerular capillary hypertension and injury in rats with desoxycorticosterone-salt hypertension. *Am J Hyper.* 3:444-450, 1990.
11. Benstein JA, Parker M, Feiner HD, **Dworkin LD**. Superiority of salt restriction over diuretics in reducing renal hypertrophy and injury in uninephrectomized SHR. *Am J Physiol.* 258:F1675-1681, 1990.
12. **Dworkin LD**, Levine RL, Benstein JA, Parker M, Feiner HD. Effects of nifedipine and enalapril on glomerular injury in rats with desoxycorticosterone-salt hypertension. *Am J Physiol.* 259:F598-F604, 1990.
13. **Dworkin LD**, Feiner HD, Parker M, Tolbert E. Effects of nifedipine and enalapril on glomerular structure and function in uninephrectomized spontaneously hypertensive rats. *Kidney Int.* 39:1112-1117, 1991.
14. Lax DS, Benstein JA, Tolbert E, **Dworkin LD**. Effects of salt restriction on renal growth and glomerular injury in rats with remnant kidneys. *Kidney Int.* 41:1527-1534, 1992.
15. **Dworkin LD**, Benstein JA, Parker M, Tolbert E, Feiner HD. Calcium antagonists and converting enzyme inhibitors reduce renal injury in rats with remnant kidneys by different mechanisms. *Kidney Int.* 43:808-814, 1993.
16. Donohue TJ, **Dworkin LD**, Lango MN, Benstein JA, Slater WR, Catanese VM. Induction of ventricular IGF-I gene expression in pressure overload hypertrophy. *Circulation*, 89:799-809, 1994.
17. **Dworkin LD**, Tolbert E, Recht PA, Hersch JC, Feiner H, Levin RI. Effects of amlodipine on glomerular filtration, growth and injury in experimental hypertension. *Hypertension.* 27:245-250, 1996
18. **Dworkin LD**, Benstein JA, Tolbert EM, Feiner HD. Salt restriction inhibits renal growth and stabilizes injury in rats with established renal disease. *JASN*, 7:437-442, 1996.
19. Hsieh F, Gohh RY, **Dworkin LD**. Acute renal failure and the MELAS syndrome, a mitochondrial encephalomyopathy. *JASN*, 7:647-652, 1996.
20. Liu Y, Tolbert EM, Sun AM, **Dworkin LD**. Primary structure of rat HGF receptor and induced expression in glomerular mesangial cells. *Am J Physiology.* 271:F679-F688, 1996.
21. Liu Y, Tolbert EM, Sun AM, **Dworkin LD**. In vivo and in vitro evidence for increased expression of HGF receptor in the kidney of diabetic rat. *Am J Physiology.* 271:F1202-F1210, 1996.

22. **Dworkin LD.** Impact of antihypertensive therapy on progression of experimental renal disease. *J of Human Hypertension.* 10:663-668, 1996.
23. Bostom AG, Shemin DG, Verhoef P, Nadeau MS, Jacques PF, Selhub J, **Dworkin LD**, Rosenberg IH. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. *Arteriosclerosis Throb Vasc Biol.* 17(11):2554-2558, Nov 1997.
24. Taman MA, Liu Y, Tolbert EM, **Dworkin LD.** Increased urinary hepatocyte growth factor excretion in human acute renal failure. *Clinical Nephrology.* 48(4):241-245, 1997.
25. Sun AM, Liu Y, **Dworkin LD**, Tse CM, Donowitz M, Yip KP. Na⁺/H⁺ exchanger isoform (NHE2) is expressed in the apical membrane of the medullary thick ascending limb. *J Membrane Biol.* 160:85-90, 1997
26. Donohue TJ, **Dworkin LD**, Junxian M, Lango M, Catanese VM. Antihypertensive agents that limit ventricular hypertrophy inhibit cardiac expression of insulin-like growth factor-I. *J of Invest Med.* 45:484-491, 1997
27. Shemin DG, **Dworkin LD.** Clinical outcome and prognosis in postpartum hemolytic uremic syndrome treated with frequent plasma exchange. *Therapeutic Apheresis.* 2(1):43-48, 1998
28. Liu Y, Centracchio J, Lin L, Sun AM, **Dworkin LD.** Constitutive expression of HGF modulates renal epithelial cell phenotypes and induces c-met and fibronectin expression. *Exp Cell Res.* 242:174-185, 1998.
29. Sun AM, Liu Y, Centracchio J, **Dworkin LD.** Expression of Na⁺/H⁺ exchanger isoforms in terminal inner medullary collecting duct (IMCDt). *J Membrane Biol,* 164:293-300, 1998.
30. Liu Y, Sun AM, **Dworkin LD.** Hepatocyte growth factor protects renal epithelial cells from apoptotic death. *Biochem Biophys Res Commun,* 246:821-826, 1998.
31. Liu Y, Tolbert EM, Lin L, Thursby MA, Sun AM, Nakamura T, **Dworkin LD.** Up-regulation of hepatocyte growth factor receptor: An amplification and targeting mechanism for hepatocyte growth factor action in acute renal failure. *Kidney Int.* 55:442-453, 1999.
32. Bostom AG, Gohh RY, Bausserman L, Hakas D, Jacques PF, Selhub, **Dworkin LD.** Serum cystatin C as a determinant of fasting total homocysteine levels in renal transplant recipients with a normal serum creatinine. *J Am Soc Nephrol.* 10:164-166, 1999.
33. Shemin D, Laplane K, Bausserman L, Kanaan E, Kahan S, **Dworkin LD**, and Bostom A. Plasma total homocysteine and hemodialysis access thrombosis: A prospective study. *J Am Soc Nephrol.* 10:1095-1099, 1999.
34. Beaulieu AJ, Laplane KL, Gohh RY, Selhub J, Monaco AP, **Dworkin LD**, Rosenberg IH, and Bostom AG. Short-term reproducibility of total homocysteine determinations in stable renal transplant recipients. *Transplant Proceedings.* 31:2121-2123, 1999.
35. Bostom AG, Gohh RY, Beaulieu AJ, Han H, Jacques PF, Selhub J, **Dworkin LD**, Rosenberg IH. Determinants of fasting plasma total homocysteine levels among stable renal transplant recipients in the era of folic acid fortified cereal grain flour. *Transplantation.* 62:257-261, 1999.

36. Bostom AG, Gohh RY, Liagaudas G, Beaulieu AJ, Han H, Jacques PF, **Dworkin LD**, Rosenberg IH, Selhub J: Prevalence of mild fasting hyperhomocysteinemia in renal transplant versus coronary artery disease after fortification of cereal grain flour with folic acid. *Atherosclerosis*, 145:221-224, 1999.
37. Bostom AG, Shemin D, Gohh RY, Beaulieu AJ, Jacques PF, **Dworkin LD**, Selhub J. Treatment of mild hyperhomocysteinemia in renal transplant recipients versus hemodialysis patients. *Transplantation*, 68:10, 1-4, 2000.
38. Tolbert E, Weisttuch J, Finer H, **Dworkin LD**. Onset of glomerular hypertension with aging precedes injury in the spontaneously hypertensive rat. *AJP:Renal Physiology*, 278:F839-F846, May, 2000.
39. Liu Y, Rajur K, Tolbert E, **Dworkin LD**. Endogenous hepatocyte growth factor ameliorates chronic renal injury by activating matrix degradation pathways. *Kidney International*, 58:5. 2028-2043, November, 2000.
40. Bostom AG, **Dworkin LD**. Cystatin C Measurement Improved Detection of Mild Decrements in Glomerular Filtration Rate Versus Certificate-Based Estimates? *Am J of Kidney Disease*, 36:205-207, 2000.
41. Bostom AG, Shemin D, Bagley P, Massy Z, Zanabli A, Christopher K, Spiegel P, Jacques PF, **Dworkin LD**, Selhub J. Controlled Comparison of L-5-Methyltetrahydrofolate Versus Folic Acid for the Treatment of Hyperhomocysteinemia in Hemodialysis Patients. *Circulation*, 101:2829-2832, 2000.
42. Yango A, Shemin D, Hsu N, Jacques PF, **Dworkin LD**, Selhub J, Bostom AG. L-folinic acid vs. folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. *Kidney International*, 59:324-327, 2001.
43. Shemin D, Bostom AG, Laliberty P, **Dworkin LD**. Residual renal function and mortality risk in hemodialysis patients. *Am J Kidney Disease*, 38:85-90, 2001.
44. Bostom AG, Shemin D, Gohh RY, Beaulieu AJ, Bagley P, Massey ZA, Jacques PF, **Dworkin LD**, Selhub J. Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients. *Kidney International*, 59(Supp 78):S246-S252, 2001.
45. Gandor H, Bagley PJ, Shemin D, Hsu N, Jacques PF, **Dworkin LD**, Bostom AG, Selhub J. Daily distribution of plasma folate forms in hemodialysis patients receiving high doses of L-folinic or folic acid. *Kidney International*, 62:2246-2249, 2002.
46. **Dworkin LD**. Antihypertensive Agents and Renal Protection: Are There Important Differences? *Nephrology Frontier*, 1(1):25-35, March, 2002
47. Yano N, Fadden-Paiva K, Endoh M, Sakai H, Kurokawa K, **Dworkin LD**, Rifai A. Profiling the IgA nephropathy renal transcriptome: analysis by complementary DNA array hybridization. *Nephrology*, 7:S140-S144, August, 2002
48. Yango A, Morrissey P, Monaco A, Gohh R, Centracchio J, **Dworkin LD**. Renal Production of HGF increases after unilateral nephrectomy in man. *Transplant Proceedings*, 34(8):3128-3129, December, 2002.

49. Yango A, Morrissey P, Zanabli A, Beaulieu, J, Shemin D, **Dworkin LD**, Monaco A, Gohh R. Comparative Study of Prophylactic Oral Gancyclovir and Valcyclovir in high-risk kidney transplant recipients. *Nephrol Dial Transplant*, 18:1-5, January, 2003
50. Gong R, Rifai A, Tolbert E, Centracchio J, **Dworkin LD**. HGF modulates matrix metalloproteinases and plasminogen activator/plasmin proteolytic pathways in progressive renal interstitial fibrosis. *J Am Soc Neph*, 14:3047-3060, December, 2003
51. **Dworkin LD**, Gong R, Tolbert E, Centracchio J, Yano N, Zanabli A, Esparza A, Rifai A. HGF ameliorates progression of interstitial fibrosis in rats with established renal injury. *Kidney International*, 65(2):409-419, February, 2004.
52. Gong R, Rifai A, Tolbert EM, Centracchio JN, **Dworkin LD**. HGF ameliorates renal interstitial inflammation in nephrectomized rats by modulating the tubular expression of MCP-1 and RANTES. *J Am Soc Neph*, 15:2868-2881, October, 2004.
53. Biswas P, Roy A, Gong R, Yango A, Tolbert E, Centracchio J, **Dworkin LD**. HGF induces an endothelin mediated decline in GFR. *Am J of Physiol, Renal Physiol*; 288(1):F8-F15, January, 2005
54. Tran MQ, Gohh RY, Morrissey PE, **Dworkin LD**, Gautam AP, Monaco AP, Yango AF. Cryptosporidium infection in renal transplant patients. *Clin Neph*, 63(4):305-309, April, 2005.
55. Gong R, Rifai A, **Dworkin LD**. Activation of PI3K-Akt-GSK3beta pathway mediates HGF inhibition of RANTES expression in renal tubular epithelial cells. *Biochem Biophys Res Commun*, 330(1):27-33, April, 2005.
56. Murphy TP, Cooper CJ, **Dworkin LD**, Henrich WL, Rundback JH, Matsumoto AH, Jamerson KA, D'Agostino RB. The Cardiovascular Outcomes with Renal Atherosclerotic Lesions (CORAL) Study: rationale and methods. *J Vasc Interv Radiol*. 16(10):1295-1300, October, 2005.
57. Gong R, Rifai A, **Dworkin LD**. Hepatocyte growth factor suppresses acute renal inflammation by inhibition of endothelial E-selectin. *Kidney Int*, 69(7):1166-1174, April, 2006.
58. Yango AF, Gohh RY, Monaco AP, Reinhart S, Gautam AP, **Dworkin LD**, Morrissey PE. Excess risk of renal allograft loss and early mortality among elderly recipients associated with poor exercise capacity. *Clin Neph*, 65:401-407, June, 2006.
59. Cooper, CJ, Murphy TP, Matsumoto A, Steffes M, Cohen DJ, Jaff M, Kuntz R, Jamerson K, Reid D, Rosenfield K, Rundback J, D'Agostino R, Henrich W, **Dworkin LD**. Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: Rationale and design of the CORAL trial. *Am Heart J*, 152(1):59-66, July, 2006
60. **Dworkin, LD**. Controversial treatment of renal artery stenosis. *Hypertension*, 48(3):350-356, September, 2006

61. Gong, R, Rifai A, **Dworkin, LD**. Anti-inflammatory effect of HGF in CKD: Targeting the inflamed vascular endothelium. *J Am Soc Neph*, 17(9):2464-2473, September, 2006
62. **Dworkin LD**, Jamerson K. The case against angioplasty and stenting of atherosclerotic renal artery stenosis. *Circulation*, 115:271-276, January, 2007
63. Yu C, Gong R, Rifai A, Tolbert EM, **Dworkin LD**. Long-term, high-dosage candesartan suppresses inflammation and injury in chronic kidney disease: nonhemodynamic renal protection. *J Am Soc Nephrol* 18(3):750-759, March 2007.

OTHER PEER-REVIEWED PUBLICATIONS

Reviews:

1. **Dworkin LD**, Brenner BM. Hormonal influences on glomerular function. *Contr Nephrol*. 33:1, 1982.
2. **Dworkin LD**, Ichikawa I, Brenner BM. Hormonal modulation of glomerular function. *Am J Physiol*. 244:F95, 1983.
3. **Dworkin LD**, Benstein JA. The role of glomerular capillary hypertension in the progression of renal disease. *Nierenund Hochdruckkrankheiten*. 1988.
4. Martinez-Maldonado M, Rodriguez-Sargent C, Cangiano JL, **Dworkin LD**. Pathogenesis of hypertension and glomerular injury in the spontaneously hypertensive rat. *Am J Cardiol*. 60:471-521, 1987.
5. **Dworkin LD**, Benstein JD. The impact of antihypertensive therapy on progressive kidney damage. *Am J Hyper*. 2:162S-172S, 1989.
6. **Dworkin LD**. Impact of calcium entry blockers on glomerular injury in experimental hypertension. *Cardiovasc Drug & Ther*. 4:1325-1330, 1990.
7. **Dworkin LD**. Effects of calcium channel blockers on experimental glomerular injury. *J Am Soc Neph*, 1:S21-S27, 1990.
8. Benstein JA, **Dworkin LD**. Renal vascular effects of calcium entry blockers in hypertension. *Am J Hyper*. 3:305S-312S, 1990.
9. **Dworkin LD**. Borderline hypertension in a patient with diabetes mellitus and a solitary kidney. *Am J Kidney Disease*. 1991.
10. **Dworkin LD**. Effects of calcium antagonists on glomerular hemodynamics and structure in experimental hypertension. *Am J Kidney Dis*. 27:89-93, 1991.
11. **Dworkin LD**. Why kidneys fail. *Mt Sinai Medical Journal*. 59:13-22, 1992.
12. Weisstuch JM, **Dworkin LD**. Does essential hypertension cause end stage renal disease? *Kidney Int*, 41:S33-S37, 1992.
13. Maher MJ, **Dworkin LD**. Update in Nephrology. *Rhode Island Medical Journal*. 1996.
14. Maher MJ, **Dworkin LD**. Calcium Channel Antagonists in the Treatment of Hypertension. *Current Opinion in Nephrology and Hypertension*. Vol. 5:437-441, 1996.

15. **Dworkin LD.** Impact of Antihypertensive Therapy on Progression of Experimental Renal Disease. *Journal of Human Hypertension*, 10:663-668,1996.
16. Shemin DG, **Dworkin LD.** Sodium Balance in Renal Failure. *Current Opinion in Nephrology and Hypertension*. 1997, vol 6/2.
17. Weir MR, **Dworkin LD.** Antihypertensive Drugs, Dietary Salt, and Renal Protection: How Low Should You Go and With Which Therapy? *Am J of Kidney Dis.* 32:1-22, 1998.
18. Moore MA, Epstein M, Agodoa L, **Dworkin LD.** Current Strategies For Management of Hypertension Renal Disease. *Arch Int Med.* 159:23-28, 1999.
19. **Dworkin LD,** Shemin DG. Antihypertensive therapy and progression of chronic renal disease. *Current Hypertension.* Vol 5:417-422, 1999.
20. Bakris GL, Williams M, **Dworkin LD,** Elliot WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J, for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving Renal Function in Adults with Hypertension and Diabetes: A Consensus Approach. *Am J of Kidney Diseases.* Vol 36, No. 3 646-661, Sept. 2000
21. **Dworkin LD.** Serum Cystatin C as a marker of glomerular filtration rate. *Current Opinion in Neph,* 10:551-553, 2001
22. Rifai A, **Dworkin LD,** Chen A. Genomic approaches to elucidating the pathophysiology of renal diseases. *Chinese Medical Journal (Taipei),* 64:555-562, 2001
23. Greenan M, **Dworkin LD.** Renal Artery Stenosis. *Nephrology Rounds,* Harvard Medical School. Vol 4, Issue 4, April 2006.

BOOKS AND BOOK CHAPTERS

Chapters:

1. **Dworkin LD,** Brenner BM. Biophysical basis of glomerular filtration. In *The Kidney: Physiology and Pathophysiology,* ed Seldin D and Giebisch G. Raven Press: New York, 1985.
2. **Dworkin LD,** Ichikawa I, Brenner BM. Glomerular filtration. In *The Kidney,* ed Brenner BM and Rector F. W.B. Saunders Co., Phila., 1986.
3. Brenner BM, **Dworkin LD.** Glomerular permselectivity. In *Proteinuria,* ed Avram MM. Plenum Pub Corp.; 1985.
4. **Dworkin LD.** ACE inhibitors and progressive kidney damage. In *Current Advances in ACE Inhibition,* ed MacGregor GA and Sever PS. Churchill Livingstone, New York, 1989.
5. **Dworkin LD,** Benstein JA. Role of glomerular hypertrophy in the progressive kidney damage of experimental hypertension. In *Diuretics III: Chemistry, Pharmacology and Clinical Applications,* ed Puschett JB. Elsevier, New York, 1990.
6. **Dworkin LD,** Brenner BM. The renal circulations. In *The Kidney,* ed Brenner BM and Rector F. W.B. Saunders Co., Phila., 1990.
7. **Dworkin LD,** Benstein JA. Antihypertensive agents, glomerular hemodynamics and glomerular injury. In *Calcium Antagonists and the Kidney,* ed Epstein M. Hanley & Belfus, Phila., 1990.

8. Benstein JA, **Dworkin LD**. Glomerular hemodynamics and experimental renal injury. In *Renovascular and Renal Parenchymatous Hypertension*, ed Luscher and Kaplan. Springer-Verlag, Germany, 1992.
9. **Dworkin LD**, Brenner BM. The biophysical basis of glomerular filtration. In *The Kidney: Physiology and Pathophysiology*, ed Seldin and Giebisch. Raven Press, New York, 1992.
10. **Dworkin LD**. Effects of renin-AII blockade on experimental renal injury. In *Current Advances in ACE Inhibition III*, ed MacGregor and Sever. Churchill Livingstone, New York, 52-55, 1993.
11. **Dworkin LD**. Progression of chronic renal failure. In *NKF Nephrology Primer*, ed Cheung, Coffman, Falk, Greenberg and Jennette. Pittsburgh, PA, 276-281, 1994.
12. **Dworkin LD**, Brenner BM. The renal circulations. In *The Kidney*, ed Brenner BM and Rector F. W.B. Saunders Co., Philadelphia, PA, 247-285, 1996.
13. **Dworkin LD**. Hypertension and the kidney: Clinical lessons from the laboratory. *Oxford University Press*, 1998
14. **Dworkin LD**, Shemin DG. Role of hypertension in progression of chronic renal disease. In *Atlas of Diseases of the Kidney*, ed Wilcox and Schrier, Philadelphia, PA, 1999.
15. **Dworkin LD**, Shemin DG. Chapter 59: Hypertension in Renal Parenchymal Disease: Role In Progression. In Brady HR and Wilcox CS, eds. *Therapy in Nephrology and Hypertension: A companion to Brenner and Rector's The Kidney*. Philadelphia: W.B. Saunders Co., 413-419, 1999.
16. **Dworkin LD**, Weir MR. Hypertension in Renal Parenchymal Disease: Role in Progression. In *Mechanisms and Clinical Management of Chronic Renal Failure*, A. Meguid El Nahas ed. Oxford University Press, 173-210, 2000.
17. Brenner B, **Dworkin LD**. The Biophysical Basis of Glomerular Filtration. *The Kidney: Physiology and Pathophysiology, 3rd Edition*. ed Seldin and Giebisch, Philadelphia, PA, 749-769, 2000
18. **Dworkin LD**, Sun AM, Brenner BM. The Renal Circulations, In *The Kidney, 6th Edition*, ed. Brenner BM., W.B. Saunders Co., Philadelphia, PA, , 277-318, 2000
19. **Dworkin LD**, Shemin DG. Chapter 56: Calcium Channel Blockers. In Brady HR and Wilcox CS, eds. *Therapy in Nephrology and Hypertension: A companion to Brenner's The Kidney, 2nd Edition*. Philadelphia: W.B. Saunders Co., 555-563, 2003
20. **Dworkin LD**, Brenner BM. The Renal Circulations, In *The Kidney, 7th Edition*, ed. Brenner BM., W.B. Saunders Co., Philadelphia, PA, 309-352, 2004

CORPORATE AUTHORSHIP OR MULTICENTER TRIALS N/A

PUBLICATIONS SUBMITTED IN PREPARTION

1. Gong R, Rifai A, **Dworkin LD**. Hepatocyte growth factor suppresses proinflammatory NF-kB activation through GSK3b inactivation in renal tubular epithelial cells. *J Biol Chem*, 2007, submitted

ABSTRACTS

1. Van Buren CT, Dudrick SJ, **Dworkin LD**, Baumbauer E, Long JM. The influence of essential L-amino acids on nitrogen metabolism in bilaterally nephrectomized dogs. *Federation Proc.* 31:2896, 1972.
2. **Dworkin LD**, Hostetter TH, Rennke HG, Brenner BM. Evidence for a hemodynamic basis for glomerular injury in hypertension. *Kidney Int.* 21:229, 1982.
3. **Dworkin LD**, Feiner HD. Evidence for hemodynamically mediated glomerular injury in uninephrectomized spontaneously hypertensive rats. *Amer Soc Nephrol.* 16:106A, 1983.
4. Levin RI, Negri AL, **Dworkin LD**. The spectrum of platelet inhibition by thromboxane synthesis inhibitor OKY046. *Clin Res.* 32:314A, 1984.
5. **Dworkin LD**, Feiner HD, Randazzo J. Evidence for hemodynamically mediated glomerular injury despite antihypertensive therapy in rats with desoxycorticosterone-salt hypertension. *Amer Soc Nephrol.* 17:91A, 1984.
6. Negri AL, Levin RL, **Dworkin LD**. Role of thromboxane A2 and prostaglandin I2 on altered glomerular function in gentamicin treated rats. *Amer Soc Nephrol.* 17:137A, 1984.
7. **Dworkin LD**, Feiner HD, Randazzo J. Increasing dietary calcium augments glomerular capillary hypertension and worsens glomerular injury in rats with desoxycorticosterone-salt hypertension. *Amer Soc Nephrol.* 18:95A, 1985.
8. Alfino P, Neugarten J, Schacht RG, **Dworkin LD**, Baldwin D. Restoration of glomerular size selective barrier by antihypertensive therapy in NSN. *Am Soc Hyper.* 1:27A, 1986.
9. **Dworkin LD**, Grosser M, Feiner HD, Ullian M, Randazzo J, Parker M. Both converting enzyme inhibitors and vasodilators reduce glomerular capillary pressure and injury in uninephrectomized spontaneously hypertensive rats. *Am Soc Nephrol.* 19:226A, 1986.
10. Alfino P, Neugarten J, Schacht RG, **Dworkin LD**, Baldwin DS. Preservation of glomerular size-selective barrier by antihypertensive therapy in nephrotoxic serum nephritis. *Am Soc Nephrol.* 19:222A, 1986.
11. Grosser M, Feiner HD, Ullian M, Parker M, **Dworkin LD**. Angiotensin converting enzyme inhibitors lessen glomerular pressure and injury, but augment arterial changes in uninephrectomized spontaneously hypertensive rats. *Am Soc Hyper.* 2:110, 1987.
12. Benstein JA, Feiner HD, Parker M, **Dworkin LD**. Therapeutic advantage of dietary sodium restriction over diuretic therapy in reducing glomerular injury in spontaneously hypertensive rats. *Am Soc Nephrol.* 20:145A, 1987.
13. **Dworkin LD**, Benstein JA, Feiner HD, Parker M. Nifedipine prevents glomerular injury without reducing glomerular pressure in rats with desoxycorticosterone-salt hypertension. *Am Soc Nephrol.* 20:227A, 1987.
14. Benstein JA, Parker M, Feiner HD, **Dworkin LD**. Salt restriction lessen renal hypertrophy and injury without reducing systemic or intrarenal pressure in rats with spontaneous hypertension. *Clin Res.* 36:513A, 1988.
15. **Dworkin LD**, Parker M, Feiner HD. Nifedipine decreases glomerular injury in rats with remnant kidneys by inhibiting glomerular hypertrophy. *Am Soc Nephrol.* 21:374A, 1988.

16. **Dworkin LD**, Parker M, Feiner HD, Tolbert E. Renal protective actions of nifedipine and enalapril: Averting the hypertrophied, hypertensive glomerulus. *Am Soc Nephrol.* 22:316A, 1989.
17. Lax DS, Benstein JA, Tolbert E, **Dworkin LD**. Dietary salt restriction decreases renal injury in rats with remnant kidneys: role of glomerular hypertrophy. *Am Soc Nephrol.* 22:323A, 1989.
18. Benstein JA, Koretz K, **Dworkin LD**, Catanese VM. Renal insulin-like growth factor-1 gene expression is increased after unilateral nephrectomy: relationship to glomerular injury. *Clin Res*, 1990.
19. Donohue TJ, **Dworkin LD**, Slater W, Catanese VM. Sequential induction of cardiac c-myc and insulin-like growth factor 1-gene expression in response elevated left ventricular afterload. *Clin Res*, 1990.
20. Donohue TJ, Benstein JA, **Dworkin LD**, Catanese VM. Sequential induction of cardiac c-myc and insulin-like growth factor-1 genes precedes ventricular hypertrophy in response to pressure overload. *Am Fed Clin Res.* Eastern Region, 1990.
21. Donohue TJ, Benstein JA, **Dworkin LD**, Slater WR, Catanese VM. Induction of cardiac insulin-like growth factor-I mRNA precedes ventricular hypertrophy in response to pressure overload. *Am Heart Assoc.* 1990.
22. **Dworkin LD**, Parker M, Tolbert M, Feiner H. Nifedipine and enalapril decrease glomerular injury in rats with remnant kidneys by different mechanisms. *JASN.* 1990.
23. Lax DS, Benstein JA, Tolbert E, **Dworkin LD**. Dietary salt restriction decreases glomerular capillary wall tension and injury in rats with remnant kidneys. *JASN.* 1990.
24. Benstein JA, Catanese VM, Lango M, **Dworkin LD**. Renal insulin-like growth factor I (IGF-I) gene expression in compensatory hypertrophy: Modulation by diet. *JASN.* 1991.
25. Weisstuch JM, Stein S, **Dworkin LD**. Blockade of endothelial derived relaxing factor (EDRF) synthesis reverses the increase in renal plasma flow (RPF) that follows unilateral nephrectomy (UNX). *JASN.* 1991.
26. Rosen RM, Tolbert E, **Dworkin LD**. Development of glomerular hypertension with aging in spontaneously hypertensive rats (SHR). *JASN.* 1991.
27. Skolnik E, Batzer A, Tolbert E, Schlessinger J, **Dworkin LD**. Protein tyrosine phosphatase activity is increased in two models of compensatory renal growth. *JASN.* 1992.
28. Benstein JA, Feiner HD, Ohsumi F, Tolbert E, **Dworkin LD**. Impact of salt restriction and calcium antagonists on renal hypertrophy, function and sclerosis in rats with remanant kidneys (RK) and established injury. *JASN.* 1992.
29. Thompson N, Catanese V, Tolbert E, **Dworkin, LD**. Insulin-like growth factor I receptors in normal and remnant rat glomeruli. *JASN.* 4:503, 1993.
30. Goldstein DC, Wheeler DJ, Sandstrom DJ, **Dworkin LD**, Manning EC, O'Meara YM, Salant DJ. Fish oil reduces proteinuria and interstitial injury but not glomerulosclerosis in the milan normotensive (MNS) rat. *JASN.* 4:769, 1993.
31. Sun AM, Nilni EA, Huo TL, **Dworkin LD**, Bookstein C, Rao, MC, Chang EB, Lytton J. Expression of NHE3 in mouse medullary thick ascending limb (MTAL). *JASN.* 5:263, 1994.

32. Shemin DG, Gohh RY, **Dworkin LD**, Bostom AG, Wilson PWF, Hartman W, Prior R, Selhub J. Prevalence and determinants of hyperhomocysteinemia in chronic renal failure. *JASN*. 5:503, 1994.
33. Thompson N, Tolbert EM, Feiner H, **Dworkin LD**. Effects of oral arginine on kidney structure and function in remnant kidney (RK) rats fed on a normal (NP) or low Protein (LP) diet. *JASN*. 5:956, 1994.
34. Shemin DG, **Dworkin LD**. Clinical outcome and prognosis in postpartum hemolytic uremic syndrome (PPHUS) treated with frequent plasma exchange (PEX). *JASN*. 6:476, 1995.
35. Sun AM, **Dworkin LD**. Presence of a basolateral Cl:HCO₃ in mouse medullary thick ascending limb (MTAL). *JASN*. 6:316, 1995.
36. Liu Y, **Dworkin LD**. Simultaneous induction of hepatocyte growth factor (HGF) and its receptor C-MET expression by interleukin-6 (IL-6) in rat glomerular mesangial cells. *JASN*. 6:771, 1995.
37. Liu Y, Tolbert EM, **Dworkin LD**. Activation of the renal hepatocyte growth factor (HGF)/cMET axis in diabetes. *JASN*. 6:1044, 1995.
38. Anderson AE, Tolbert EM, Esparza AR, **Dworkin LD**. Discordant effects of an angiotensin converting enzyme inhibitor (ACEI) VS an AII receptor antagonist (AA) on blood pressure and renal damage in spontaneously hypertensive rats (SHR). *ASH*. 1996.
39. Taman MA, Liu Y, Tolbert E, **Dworkin LD**. Urinary hepatocyte growth factor (HGF) levels increase in patients with acute tubular necrosis (ATN). *NKF*. 1996.
40. Sun AM, Yip KP, Liu Y, Centracchio JN, Tse CM, Donowitz M, **Dworkin, LD**. NHE-2 is present in the apical membrane of medullary thick ascending limb (MTAL). *ASN*. 1996.
41. Liu Y, Tolbert E, Sun A, **Dworkin LD**. Primary structure of rat hepatocyte growth factor receptor and rapid induction of expression in acute renal injury. *ASN*. 1996.
42. Anderson AE, Tolbert E, Esparza AR, **Dworkin LD**. Effects of an ACE inhibitor (ACEI) VS. and AII antagonist (AA) on hemodynamics, growth and injury in spontaneously hypertensive rats (SHR). *ASN*. 1996.
43. Taman M, Liu Y, Tolbert E, **Dworkin LD**. Urinary hepatocyte growth factor (HGF) excretion in patients with renal disease. *ASN*. 1996.
44. Sun AM, Liu Y, Centracchio JN, Tolbert EM, **Dworkin, LD**. Na/H exchanger (NHE) isoform expression and function in terminal inner medullary collecting duct (IMCD). *JASN*. 1997.
45. Liu Y, Centracchio JN, Lin L, Sun AM, **Dworkin LD**. Autocrine expression of HGF and its receptor modulates renal epithelial cell phenotype and fibronectin expression. *JASN*. 1997.
46. Liu Y, Sun AM, **Dworkin, LD**. The human hepatocyte growth factor receptor gene: Structural organization and promoter characterization. *JASN*. 1997.
47. Plager M, Liu Y, Tolbert E, **Dworkin LD**. Biphasic, sequential induction of c-fos, c-jun, hepatocyte growth factor (HGF) HGF receptor (c-met) and TGF- β precedes renal injury in the rat remnant kidney. *JASN*. 1997

48. Parsa A, Dworkin LD. Angiotensin II binding to type 1 receptors promotes glomerular apoptosis and injury in remnant kidney rats. *ASN*. 1997
49. Tolbert EM, **Dworkin LD**. Altered responsiveness to angiotensin II in aging SHR causes glomerular hypertension. *Am J of Hypertension*. 1998
50. Rajur K, Kumar A, Parsa A, Tolbert E, Lin L, Liu Y, **Dworkin LD**. Incomplete suppression of TGF- β and fibronectin gene expression and glomerular injury in remnant kidney rats by angiotensin II (AII) type 1 receptor blockade (ARB). *ASN*. 1998
51. Rajur K, Parsa A, Esparza A, Tolbert E, Liu Y, **Dworkin LD**. Activation of the renal hepatocyte growth factor/c-met axis preserves structure and function in remnant kidney rats. *ASN*. 1998
52. Liu Y, Lin L, Sun AM, **Dworkin LD**. Hepatocyte growth factor prevents renal interstitial fibrosis by activating matrix degradation pathways. *ASN*. 1998
53. Liu Y, Sun AM, **Dworkin LD**. Hepatocyte growth factor protects renal epithelial cells from apoptotic cell death. *ASN*, 1998
54. Kanaan E, Shemin D, Lapanc K, Bausserman L, Sewell K, Laliberty P, Stein D, Plager M, **Dworkin LD**, Bostom, A. Total homocysteine levels predict hemodialysis access thrombosis: A prospective study. *ASN*. 1998
55. Patel KN, Liu Y, Centracchio J, Soleimani M, **Dworkin LD**, Sun AM. Activation of NHE1 by hyperosmolality involves tyrosine phosphorylation and dephosphorylation in inner medullary collecting duct (IMCD). *ASN*. 1998
56. Hakas D, Gohh RY, Bausserman L, Jacques P, **Dworkin LD**, Rosenberg I, Selhub J, Bostom AG. Serum cystatin C, a sensitive indicator of glomerular filtration rate, independently predicts fasting total homocysteine levels in renal transplant recipients with normal serum creatinine. *JASN*. 9:668A, 1998
57. Bostom AG, Gohh RY, Lapane K, Jacques P, **Dworkin LD**, Rosenberg IH, Selhub J. Divergent impact of folic acid fortification of cereal grain flour on the prevalence of mild fasting hyperhomocysteinemia in renal transplant versus coronary artery disease patients. *JASN*. 9:667A, 1998.
58. Zanabli A, Yango A, **Dworkin LD**. Hyperkalemia in outpatients on angiotensin converting enzyme inhibitors (Lisinopril) vs. angiotensin II receptors blockers (Losartan). *ASN*, 2000.
59. Bostom AG, Shemin D, Beaulieu A, Gohh RY, Jacques PF, **Dworkin LD**, Selhub J. The hyperhomocysteinemia of hemodialysis patients is much more refractory to treatment compared to renal transplant recipients with equivalent baseline total homocysteine levels. *ASN*, 2000.
60. Bostom AG, Shemin D, Bagley P, Massy ZA, Zanabli A, Spiegel P, Jacques P, Christopher K, **Dworkin LD**, Selhub J. Reduced folates are an expensive treatment for hyperhomocysteinemia hemodialysis patients with no greater efficacy than folic acid: Results of a controlled comparison study. *ASN*, 2000

61. Yano N, Fadden K, Yamashita H, Endoh M, Sakai H, Kurokawa K, **Dworkin LD**, Rifai A. The genomic response of human renal epithelial cells to angiotensin II: Comprehensive analysis by cDNA microarray hybridization. *ASN*, 2000
62. Yango A, Gohh RY, Morrisey P, Centracchio J, **Dworkin LD**. Renal production of hepatocyte growth factor increases after unilateral nephrectomy in man. *ASN*, 2000
63. **Dworkin LD**, Zanabli A, Tolbert E. HGF reduces injury and alters glomerular hemodynamics in rats with remnant kidneys. *ASN*, 2000.
64. Yano H, Tolbert E, Fadden K, Rifai A, **Dworkin LD**. Alteration in gene expression profile in rat remnant kidney: A comprehensive analysis by high-density cDNA array hybridization. *ASN*, 2000.
65. Zanabli A, Tolbert E, **Dworkin LD**. Superiority of high dose angiotensin II receptor blockade (ARB) in preventing injury in uninephctomized (UNX) spontaneously hypertensive rats (SHR). *ASN*, 2000.
66. Shemin D, Bostom AG, Laliberty P, Kahn SI, **Dworkin LD**. The effect of residual renal function on mortality in hemodialysis patients. *ASN*, 2000.
67. Roy A, Tolbert E, Centracchio J, Yango A, **Dworkin LD**. HGF induces an endothelin-mediated decline in renal plasma flow and GFR in rat. *ASN*, 2001.
68. **Dworkin LD**, Tolbert E, Zanabli A. Effects of very high dose angiotensin II receptor blockate (ARB) on kidney structure and function in uninephctomized (UNX) spontaneously hypertensive rats (SHR). *ASN*, 2001
69. **Dworkin, LD**, Roy A, Tolbert E, Centracchio J, Yango A. HGF induces rapid, sustained decline in GFR: Role of endothelin and angiotensin II. *ASN*, 2002
70. Gong R, Centracchio J, Tolbert E, Rifai A, **Dworkin LD**. Effects of HGF and TGF- β on extracellular matrix composition in cultured tubular epithelial cells: Potential role in tissue remodeling. *ASN*, 2002
71. Smyth B, Tolbert E, Centracchio J, Paiva K, Rifai A, **Dworkin LD**. Rapid induction by angiotensin II of immediate early genes in rat proximal tubule *in vivo*. *ASN*, 2002
72. Gong R, Rifai A, Tolbert E, Biswas P, Centracchio J, **Dworkin LD**. HGF ameliorates renal interstitial fibrosis by modulating matrix metalloprotenases (MMP's) and plasminogen activator (PA)/plasmin proteolytic pathways. *ASN*, 2003
73. Gong R, Tolbert E, Biswas P, Rifai A, **Dworkin LD**. Role of HGF in attenuating proteinuria and fibrosis in the rat remnant kidney model by angiotensin II (AngII) antagonism. *ASN*, 2003
74. Cardinale CJ, Ko K, **Dworkin LD**, Shaw AS, Skolnik EY. A potential role for integrin β 6-mediated activation of TGF- β in the progression of chronic renal disease. *ASN*, 2003

75. Yango A, Gohh R, Monaco A, Guatam A, **Dworkin LD**, Morrissey P. Excess risk of renal allograft loss and early mortality among elderly renal transplant recipients associated with poor exercise capacity. *XX Int Congress of the Transplantation Soc*, 2004
76. Gong R, Rifai A, Tolbert E, Biswas P, **Dworkin LD**. HGF ameliorates renal interstitial inflammation in rat remnant kidney by modulating tubular expression of MCP-1 and RANTES. *ASN*, 2004
77. Biswas P, Roy A, Gong R, Centracchio J, Tolbert E, **Dworkin LD**. HGF mediates renal hemodynamics and injury progression via endothelin-1. *ASN*, 2004
78. Gong R, Rifai A, **Dworkin LD**. Activation of phosphatidylinositol 3-kinase (PI3K)-Akt-glycogen synthase kinase (GSK)3. Pathway mediates HGF inhibition of RANTES expression in renal tubular epithelial cells. *ASN*, 2005
79. Gong R, Tolbert EM, **Dworkin LD**. HGF suppresses acute renal inflammation by inhibition of endothelial e-selectin. *ASN*, 2005.
80. Gong R, Rifai A, Tolbert EM, **Dworkin LD**. The anti-inflammatory effect of HGF in CKD: Targeting the inflamed vascular endothelium. *ASN*, 2006
81. Ham MW, Aboagye-Kumi MY, Gong R, **Dworkin LD**. LPS injection ameliorates experimental renal inflammation and injury via inhibition of NF- κ B. *ASN*, 2006
82. Eckert S, Gong R, **Dworkin LD**. HGF is a potent anti-inflammatory cytokine targeting inflamed endothelial cells. *ASN*, 2006.
83. Yu C, Gong R, **Dworkin, LD**. Anti-Inflammatory effects of high-dose candasartan do not depend on blockade of angiotensin II type 1 receptors. *ASN*, 2006
84. Yu C, Gong R, Tolbert EM, **Dworkin LD**. High-dose candasartan suppresses inflammation and injury in chronic kidney diseases: On beyond hemodynamics. *ASN*, 2006

SCHOLARY WORK PUBLISHED IN OTHER MEDIA N/A

INVITED PRESENTATIONS

1. Symposium on “The Future of Nephrology” University of Erlangen-Nurnberg. Nurnberg, G.D.R. February, 1987
2. Symposium on “Hormonal Regulation of Glomerular Function.” Canadian Society of Nephrology Annual Meeting. Winnipeg, Canada. September, 1987
3. George A. Anderson, MD Memorial Lecture in Diabetes, Brooklyn Society of Internal Medicine. March, 1988
4. Symposium on “Renal and Cardiovascular Injury: The Role of Calcium Antagonists.” 21st Annual Meeting of the American Society of Nephrology. San Antonio, Texas. December, 1988
5. The International Symposium on ACE Inhibition. London, England. February, 1989
6. The Third International Conference on Diuretics. Mexico City, Mexico. April, 1989
7. Inter-American Society of Hypertension. 8th Scientific Meeting. San Juan, P.R. May, 1989

8. American Society of Hypertension. 4th Scientific Meeting. New York, N.Y. May, 1989
9. International Conference on Progression of Renal Disease. Verona, Italy. September, 1990
10. National Kidney Foundation Annual Scientific Meeting Symposium on "Avoiding the Progression of Renal Injury: Current Topics and Clinical Implications." December, 1990
11. International Symposium on ACE Inhibition. Member, program committee. London, England. 1991
12. International Workshop on Renal Protective Aspects of Calcium Antagonists. Florence, Italy. April, 1991
13. Forum on Cardiovascular Therapy - Calcium Antagonists: Cardiovascular and Renal Disease. New Orleans. April, 1991
14. Renal Roundtable for Kansas and Missouri Nephrologists. Kansas Kidney Foundation, Kansas City. September, 1991
15. Symposium on Antihypertensive Therapy and Progression of Renal Disease. Annual Meeting of the Royal Society of Physicians and Surgeons of Canada. Quebec City, Canada. September, 1991
16. American Society of Hypertension. 7th Scientific Meeting. New York, May, 1992
International Symposium on Lipids and Vasoactive Agents in Renal Disease, Long Island College Hospital. New York. October, 1992
17. Second European Nitrendipine Symposium: The Kidney in Hypertension. Istanbul, October, 1992
18. Fourth International Conference on Diuretics. Boca Raton, Florida. October, 1992
19. Third International Symposium on ACE Inhibition. Amsterdam, The Netherlands, March 1993
20. Rhode Island ACP Fall Conference. Newport, Rhode Island, October, 1994
21. Fourth International - 2nd Asian-Pacific Symposium on ACE Inhibition & Other Inhibitors of the Renin-Angiotensin System. Beijing, China, April, 1995
22. International Society of Hypertension. Glasgow, Scotland, June, 1996
23. Tony Raine Memorial Symposium on Hypertension and the Kidney. Glasgow, Scotland. June, 1996
24. Third Asian-Pacific Symposium on ACE Inhibition and Other Inhibitors of the Renin-Angiotensin System. Hong Kong, China, April, 1997
25. National Kidney Foundation Spring Meeting. Boston, MA, June, 1997
26. American Diabetes Association, 57th Annual Scientific Session. Boston, MA. June, 1997
27. Chief Medical Residents Conference. Hilton Head, SC. September, 1997
28. American College of Physicians, Rhode Island Chapter's Internal Medicine Update. Newport, RI. November, 1997
29. 17th Scientific Meeting of the International Society of Hypertension. Prague, Czech Republic. June, 1998
30. 16th Annual Meeting of the International Blood Purification. Newport, RI. October 4-6, 1998.
31. 10th International Symposium of Nephrology. Skovde, Sweden. September, 1998
32. Angiotensin II Receptor Blockade: Effects Beyond Blood Pressure Control. Prague, Czech Republic. June, 2000
33. American Society of Nephrology 33rd Annual Meeting Hypertension: Debates, Updates, and Workshops. Co-sponsored by the American Society of Hypertension. Toronto, Ontario, Canada. October 12, 2000.
34. American College of Physicians, Rhode Island Fall Update in Internal Medicine. Newport, RI. November, 2000

35. Rhode Island Academy of Family Physicians, Primary Care Update. Newport, RI. March 16, 2001.
36. Tokai and Osaka Universities, Japan, Visiting Professor. August 1-10, 2001.
37. Harvard Medical School, Intensive Board Review and Contemporary Issues in Nephrology. August 26, 2001.
38. 5th Congreso Internacional Dr. Marieni Cabral, Terapia antihipertensiva para disminuir la progresion de fallo renal cronico. Tratamiento de hipertension leve a moderada. Santo Domingo, DR. May 8-10, 2003.
39. American Heart Association Scientific Sessions 2003, Cardiovascular Seminars. Renovascular Hypertension and Ischemic Nephropathy: A Costly, Invasive and Sometimes Dangerous Work-Up Without Objective Evidence of Benefit. Orlando, FL. November 9, 2003.
40. American Society of Nephrology 36th Annual Meeting and Scientific Exposition. The Hypertensive Diabetic with CKD: Initiating the Best Therapeutic Regimen at the Official Evening Symposium. San Diego, CA. November 15, 2003.
41. American College of Physicians, Rhode Island Chapter Scientific Meeting. Diabetes Symposium – Comprehensive Care of the Diabetic Patient. Hypertension and Nephropathy in Type II Diabetics: Is a Handful of ACE's Enough to Win? Warwick, RI, May 5, 2004.
42. American Society of Nephrology, Hypertension Research Retreat, Washington, DC, November 15-16, 2004
43. Harvard Medical School, Intensive Board Review and Contemporary Issues in Nephrology. Ischemic Nephropathy. September 11, 2005
44. Baystate Medical Center, Chestnut Conference Center. Controversies in Renal Vascular Disease. Medical Treatment of Renal Vascular Disease. Springfield, MA, September 28, 2005
45. American Society of Nephrology 38th Annual Meeting and Scientific Exposition. Hypertension: CKD and CVD:Strategies to Evaluate and Reduce Risks. “What’s New in Renal Artery Stenosis? The CORAL Trial”. Philadelphia, PA. November 9, 2005.
46. American Heart Association Scientific Sessions, 2005, Renal Vascular Disease: A Time to Focus on Proper Identification and Treatment of High-Risk Individuals, Dallas, TX, November 14, 2005
47. Emory University, Medical and Renal Grand Rounds. On Beyond ACE’s: Uncovering the Multiple Renal Protective Actions of HGF. Atlanta, GA, March 28, 2006.
48. Holy Name Hospital/Medical Society of New Jersey. Renal Vascular Disease: Diagnosis, Treatment, and Clinical Study Symposium. “Controversial Treatments of RAS”. Newark, NJ. April 5, 2006.
49. American Society of Hypertension 21st Annual Scientific Meeting and Exposition: Characterizing the Hypertension Phenotypes “The Controversial Treatment of Renal Artery Stenosis: The CORAL Trial”. New York, NY. May 19, 2006.
50. Foundation for the Prevention of Cardiovascular Risk, Cardio-Renal Meeting: “Hypertension, Renovascular Disease, and Conduit Vessel Function”. New York, NY, March 29, 2007
51. Jinling Hospital, Nanjing University School of Clinical Medicine, Visiting Professor. “Renal Artery Stenosis: Controversies and the CORAL Trial”, “Renal Protection with AII Receptor Blockers: Beyond Hemodynamics, Usual Doses and the AT1 Receptor”. Nanjing, China, May 20-June 1, 2007.
52. Centers for Medicare and Medicaid Services, Invited Presenter, Medical Coverage Advisory Committee meeting to examine the best treatment for patients with atherosclerotic renal artery stenosis and to develop a national coverage determination for the treatment of renal artery stenosis. Baltimore, MD, July 18, 2007

Invited Lectures at Universities and Medical Schools:

Albert Einstein College of Medicine, 1992
Baystate Medical Center. Springfield, MA, 1996, 2005
Booth Memorial Medical Center. Flushing, NY, 1993
Boston University, 1992
Brigham and Women's Hospital, 1992
Brown University, 1991, 2003, 2005
Case Western Reserve University, 1993
Columbia University, 1993, 2000
Cornell University, 1994
Emory University, 2006
George Washington University, 1991
Georgetown University, 2000
FDR/VA Hospital, Mount Rose, NY, 1993
Hannemahn University, 1991, 2001
Harvard University, 1992, 2001, 2005, 2006
Hennipin County Medical Center, 1994
Holy Name Hospital, Newark, NJ, 2006
Kennedy Memorial Hospital. Stratford, NJ, 1995
Long Island College, 1992
Massachusetts General Hospital, 2000
Mayo Clinic, 1991
Medical College of Wisconsin, 1999
Mount Sinai School of Medicine, 1991
Nanjing University, Nanjing, China, 2007
New England Medical Center, 1991
New York Medical College, 1992, 2000
New York Methodist Hospital, 1999, 2007
New York University, 2004
Rhode Island Hospital, 1993-present
Presbyterian University Hospital, 1991
Providence VA Medical Center, 1993
Roger Williams Medical Center, 1993
Rush Medical College, 1994
St. Anne's Hospital. Fall River, MA, 1995
St. Luke's Hospital. Kansas City, MO, 1991
St. Luke's Medical Center, Milwaukee, WI, 2007
State University of New York, Stony Brook, 1996
Temple University, 1991
Texas Tech School of Medicine, 1991
The Miriam Hospital, 1993
Thomas Jefferson University, 1992
Tokai University, Tokyo Japan, 2001
Trumane Medical Center. Kansas City, MO, 1991
Tufts University, 1991
Tulane University, 1991

University of Alabama, Birmingham, 1992
University of Chicago, 1992
University of Florida, Gainesville, 1992
University of Illinois, 1992
University of Iowa, 1993
University of Maryland School of Medicine, 1994
University of Massachusetts, 1992, 2000
University of Medicine and Dentistry of New Jersey, 1992
University of Miami, 1991, 2007
University of Minnesota, 1993
University of Missouri, Kansas, 1991
University of North Carolina, 1994
University of Pittsburgh, 1994
University of Texas, San Antonio, 1991
University of Texas, Southwestern Medical Center, 1991, 2007
University of Toronto, 1993
University of West Virginia, 1993
University of Wisconsin, 1994
Wake Forest University, 1995
Washington University School of Medicine, 1996
Westchester County Medical Center. Valhalla, NY, 1991, 2000
Westerly Hospital. Westerly, RI, 1993
Winthrop University Hospital, 1991
Worcester Medical Center/St. Vincent's Hospital, 2005
Yale University, 1992
Veterans Administration Medical Center. Providence, RI, 1993, 2000

GRANTS

1. Project Title: Structure and function of the glomerular microcirculation in hypertension
Role: Principal Investigator
Sponsoring Agency: New York University Medical Center
Period of Support: 3/1/83-8/13/84
Amount of Support: \$10,000
2. Project Title: The renal glomerulus in experimental hypertension
Role: Principal Investigator
Sponsoring Agency: New York University Medical Center
Period of Support: 9/1/83-8/31/84
Amount of Support: \$10,000
3. Project Title: Pathogenesis and prevention of glomerular injury in experimental hypertension
Role: Principal Investigator
Sponsoring Agency: The Irma T. Hirschl Charitable Trust Career Scientist Award
Period of Support: 1/1/85-12/31/89
Amount of Support: \$20,000 per annum, total \$100,000
4. Project Title: The renal glomerulus in experimental hypertension
Role: Principal Investigator
Sponsoring Agency: National Institutes of Health New Investigator Award
Period of Support: 4/1/84-3/31/87
Amount of Support: \$107,500
5. Project Title: Effects of chronic administration of Captopril and Hydralazine on renal hemodynamics in rats with heart failure
Role: Principal Investigator
Sponsoring Agency: Squibb & Sons, Inc.
Period of Support: 9/1/84-8/31/85
Amount of Support: \$20,000
6. Project Title: Mechanisms of glomerular injury in experimental hypertension
Role: Principal Investigator
Sponsoring Agency: Evans Foundation
Period of Support: 7/1/85-6/30/86
Amount of Support: \$18,000
7. Project Title: Glomerular injury in experimental hypertension
Role: Principal Investigator
Sponsoring Agency: Evans Foundation
Period of Support: 7/1/86-6/30/87
Amount of Support: \$18,000
8. Project Title: Glomerular injury in experimental hypertension
Role: Principal Investigator
Sponsoring Agency: Evans Foundation

Period of Support: 7/1/87-6/30/88
Amount of Support: \$22,500

9. Project Title: Glomerular injury in experimental hypertension
Role: Principal Investigator
Sponsoring Agency: Evans Foundation
Period of Support: 7/1/88-6/30/89
Amount of Support: \$22,500

10. Project Title: Effects of Nifedipine on renal hemodynamics and glomerular injury in rats with experimental hypertension
Role: Principal Investigator
Sponsoring Agency: Pfizer, Inc.
Period of Support: 9/1/86-12/31/89
Amount of Support: \$205,530

11. Project Title: Progressive glomerular injury: Pathogenesis and prevention
Role: Principal Investigator
Sponsoring Agency: National Institutes of Health, RO1
Period of Support: 9/20/87-8/31/90
Amount of Support: \$255,441

12. Project Title: Glomerular injury in experimental hypertension
Role: Principal Investigator
Sponsoring Agency: Evans Foundation
Period of Support: 1/1/89-10/31/90
Amount of Support: \$18,000

13. Project Title: Glomerular injury in experimental hypertension
Role: Principal Investigator
Sponsoring Agency: Evans Foundation
Period of Support: 11/1/90-10/31/91
Amount of Support: \$25,000

14. Project Title: Mechanisms of glomerular injury in experimental hypertension
Role: Principal Investigator
Sponsoring Agency: Evans Foundation
Period of Support: 7/1/91-6/30/92
Amount of Support: \$22,500

15. Project Title: Effect of Amlodipine on kidney damage in experimental hypertension
Role: Principal Investigator
Sponsoring Agency: Pfizer Labs, Inc.
Period of Support: 6/1/91-10/30/92
Amount of Support: \$117,500

16. Project Title: Effects of felodipine and enalapril on glomerular injury
Role: Principal Investigator

Sponsoring Agency: Merck/Astra
Period of Support: 3/1/92-8/31/93
Amount of Support: \$93,216

17. Project Title: Role of IGF-I in progressive glomerular injury
Role: Principal Investigator
Sponsoring Agency: American Heart Association/N.Y. affiliate
Period of Support: 7/1/92-6/30/95
Amount of Support: \$135,000

18. Project Title: Role of Renal IGF-I in diabetic nephropathy
Role: Co-Investigator
Sponsoring Agency: National Institutes of Health, RO1
Period of Support: 9/30/90-8/31/95
Amount of Support: \$657,002

19. Project Title: The effects of an angiotensin II receptor antagonist on glomerular injury in spontaneously hypertensive rats
Role: Principal Investigator
Sponsoring Agency: Bristol-Myers Squibb Company
Period of Support: 9/1/94-8/31/96
Amount of Support: \$83,344.00

20. Project Title: Diltiazem ER/Enalapril Combination therapy in hypertensive patients not responding adequately to Diltiazem CD Monotherapy
Role: Principal Investigator
Sponsoring Agency: Marion Merrell Dow, Inc.
Period of Support: 1/24/94-1/23/95
Amount of Support: \$59,625.00

21. Project Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial of ANA-756 in patients with essential hypertension
Role: Principal Investigator
Sponsoring Agency: Wyeth-Ayerst
Period of Support: 3/94-9/94
Amount of Support: \$66,260.00

22. Project Title: A Multicenter, Double-Blind, Randomized, Parallel-Group Study to investigate the incidence of cough in patients receiving Losartan Potassium (50mg once daily), Lisinopril (20mg once daily) or Placebo, who have reported cough with an angiotensin converting enzyme inhibitor
Role: Principal Investigator
Sponsoring Agency: Merck
Period of Support: 7/27/93-7/26/94
Amount of Support: \$14,724.00

23. Project Title: Losartan QD vs BID Efficacy Study
Role: Principal Investigator
Sponsoring Agency: Merck

Period of Support: 7/1/92-5/31/95
Amount of Support: \$18,000.00

24. Project Title: Irbesartan in Type II DM
Role: Principal Investigator
Sponsoring Agency: Bristol-Myers Squibb
Period of Support: 4/1/95-3/31/96
Amount of Support: \$38,515.00

25. Project Title: Evaluation of the Safety and Efficacy of Maintenance Therapy with Oral ANA-756 in the treatment of patients with essential hypertension
Role: Principal Investigator
Sponsoring Agency: Wyeth-Ayerst
Period of Support: 1995 - 1998
Amount of Support: \$195,000.00

26. Project Title: Irbesartan in Type II DM
Role: Principal Investigator
Sponsoring Agency: Bristol Myers Squibb
Period of Support: 1996 - 1999
Amount of Support: \$55,701

27. Project Title: Auriculin Anaritide
Role: Principal Investigator
Sponsoring Agency: Scios Nova
Period of Support: 1996-1997
Amount of Support: \$37,450 (Based on patient recruitment)

28. Project Title: Losartan Factorial
Role: Principal Investigator
Sponsoring Agency: Merck & Co., Inc.
Period of Support: 1996-1997
Amount of Support: \$64,694

29. Project Title: Effects of Accupril on blood pressure and renal injury: comparison with a lipophilic ACE inhibitor and an AII antagonist
Role: Principal Investigator
Sponsoring Agency: Parke Davis
Period of Support: 1996-1998
Amount of Support: \$40,000

30. Project Title: Comparison of the Safety and Antihypertensive Efficacy of the Fixed Combination of Candasartan Cilxetil and Hydrochlorothiazide (32/12.5mg) Once Daily with the Individual Components Administered Once Daily
Role: Principal Investigator
Sponsoring Agency: Pharmaceutical Research Associates
Period of Support: 1997-1998
Amount of Support: \$28,512.00

31. Project Title: Evaluation of the Antihypertensive Effect of Candesartan Cilexetil in Comparison to Losartan: A Double Blind, Multicenter, Parallel Design, Randomized Study
Role: Principal Investigator
Sponsoring Agency: Astra Merck Inc.
Period of Support: 1997-1998
Amount of Support: \$24,800

32. Project Title: Losartan Intervention for Endpoint Reduction in Hypertension
Role: Principal Investigator
Sponsoring Agency: Merck & Co.
Period of Support: 1996 - 2000
Amount of Support: \$67,000

33. Project Title: Physiologic & Pathogenic Actions of Renal HGF/C
Role: Principal Investigator
Sponsoring Agency: American Heart Association
Period of Support: 7/1/98-6/30/00
Amount of Support: \$60,000

34. Project Title: A Double-Blind, Placebo-Controlled, Randomized, Study to Evaluate the Safety and Efficacy of Ranging Doses of Eplerenone Relative to Placebo, Hydrochlorothiazide and Daily Dose Combinations of Eplerenone and HCTZ for the treatment of Mild to Moderate Hypertension.
Role: Principal Investigator
Sponsoring Agency: Searle & Co.
Period of Support: 4/1/99-3/31/00
Amount of Support: \$36,000

35. Project Title: Dose Dependency of Renal Protective Effects of Candesartan Cilexetil in Experimental Renal Disease
Role: Principal Investigator
Sponsoring Agency: Astra Pharmaceuticals
Period of Support: 1/1/99-12/30/01
Amount of Support: \$86,288

36. Project Title: Physiologic & Pathogenic Actions of Renal HGF/c-met (Administrative Supplement for Gene Profiling Resources)
Role: Principal Investigator
Sponsoring Agency: National Institute of Health
Period of Support: 8/15/00-4/30/01
Amount of Support: \$35,000

37. Project Title: Omapatrilat Cardiovascular Treatment Assessment vs. Enalapril (OCTAVE)
Role: Principal Investigator
Sponsoring Agency: Bristol-Myers Squibb
Period of Support: 12/28/00-5/31/01
Amount of Support: \$22,500

38. Project Title: The Effect of Irbesartan on Morbidity and Mortality in Hypertensive Patients with Type II Diabetes and Diabetic Nephropathy

Sponsoring Agency: Bristol-Myers Squibb

Role: Principal Investigator

Period of Support: 2/1/98-7/31/01

Amount of Support: \$72,200

39. Project Title: A Double-Blind, Randomized, Placebo and Active Controlled, Parallel Group, Dose-Finding Study to Evaluate the Efficacy and Safety of Once Daily Oral Administration of 5mg, 10mg, 25 mg, and 50 mg of M100240...

Sponsoring Agency: Aventis Pharmaceuticals

Role: Principal Investigator

Period of Support: 9/21/01-10/31/02

Amount of Support: 65,000

40. Project Title: Antihypertensive Efficacy of Adding Candesartan Cilexetil to Lisinopril in Comparison to Up-Titration of Lisinopril (AMAZE)

Sponsoring Agency: AstraZeneca

Role: Principal Investigator

Period of Support: 7/19/01-8/01/02

Amount of Support: 25,000

41. Project Title: Candesartan in Spontaneously Hypertensive Rats

Sponsoring Agency: AstraZeneca

Role: Principal Investigator

Period of Support 1/1/99-12/31/02

Amount of Support: \$120,000

42. Project Title: A Double-Blind, Multi-Center, Randomized, Placebo-Controlled, Parallel Group Study of the Effects of Nebivolol on Safety and Efficacy in Patients with Mild to Moderate Hypertension

Sponsoring Agency: Bertek Pharmaceuticals

Role: Principal Investigator

Period of Support: 1/28/02-2/01/03

Amount of Support: 39,000

43. Project Title: A prospective, multinational multicenter, double-blind, randomized active controlled trial in patients with essential hypertension to compare the effect of Valsartan 80mg & 160mg with or without the addition of Hydrochlorothiazide, once daily to that of Amlodipine 5 & 10mg once daily, with or without the addition of Hydrochlorothiazide, on cardiovascular morbidity and mortality.

Role: Principal Investigator

Sponsoring Agency: Novartis

Period of Support: 4/7/98-3/31/04

Amount of Support: \$113,932

44. Project Title: A randomized, placebo-controlled, multicenter trial evaluating a) alternate day Prednisone b) fish oil supplements in young patients with IgA nephropathy
Role: Principal Investigator
Sponsoring Agency: National Institute of Health
Period of Support: 4/7/98-3/31/03
Amount of Support: \$15,550
45. Project Title: A multicenter, double-blind, randomized, parallel group, 6-week study to evaluate the efficacy and safety of Ezetimibe/Simvastatin combination
Role: Principal Investigator
Sponsoring Agency: Merck & Co.
Period of Support: 8/12/03-7/31/04
Amount of Support: \$18,840
46. Project Title: Multicentered, randomized, double-blind, placebo-controlled, efficacy and safety study of the effects of oral Tolvaptan in patients with hyponatremia
Role: Principal Investigator
Sponsoring Agency: Otsuka
Period of Support: 4/1/03-11/31/04
Amount of Support: 28,950
47. Project Title: A multicenter, double-blind, randomized, parallel group study to evaluate the effects of Diovan on microalbuminuria in hypertensive subjects with type II diabetes.
Role: Principal Investigator
Sponsoring Agency: Novartis
Period of Support: 11/1/02-4/31/04
Amount of Support: \$46,812
48. Project Title: Clinical Protocol for a multicenter, placebo-run, randomized, double-blind, parallel group trial to evaluate the effects of Eplerenone vs. Eplerenone/Lisinopril
Role: Principal Investigator
Sponsoring Agency: Pharmacia
Period of Support: 12/1/02-1/1/03
Amount of Support: \$34,546
49. Project Title: A multicenter, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of the co-administration of Simvastatin 20mg/day
Sponsoring Agency: Merck & Co.
Role: Principal Investigator
Period of Support: 4/1/02-3/31/03
Amount of Support: \$25,000
50. Project Title: A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy
Role: Principal Investigator
Sponsoring Agency: Medical City Dallas Hospital
Period of Support: 12/2/02-6/30/07
Amount of Support: \$30,000

51. Project Title: A randomized, double-blind, placebo-controlled, parallel group evaluation of the effects of lipid-lowering therapy with Simvastatin and Ezetimibe compared with placebo on time to a first cardiovascular event

Role: Principal Investigator

Sponsoring Agency: University of Oxford

Period of Support: 2/10/04-1/31/09

Amount of Support: \$30,000

52. Project Title: Physiologic & Pathogenic Actions of Renal HGF/c-met

Role: Principal Investigator

Sponsoring Agency: National Institute of Health

Period of Support: 5/1/99-4/30/04

Amount of Support: \$898,867

53. Project Title: Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL)

Role: Principal Investigator (Study Chair)

Sponsoring Agency: National Institute of Health

Period of Support: 5/1/04-4/30/10

Amount of Support: \$534,535

54. Project Title: A multi-center, open-label, randomized phase II study to assess safety, duration of treatment (up to 72 hours) and preliminary efficacy with the Renal Assist Device (RAD) in patients with Acute Renal Failure (ARF).

Role: Principal Investigator

Sponsoring Agency: Nephros Therapeutics

Period of Support: 3/29/05-3/1/06

Amount of Support: \$360,557

55. Project Title: The effect of Sulodexide in overt type 2 diabetic nephropathy.

Role: Principal Investigator

Sponsoring Agency: Keryx

Period of Support: 3/1/05-12/1/09

Amount of Support: \$121,380

56. Project Title: A twelve week double blind, randomized multicenter parallel group study to evaluate the efficacy and safety of orally administered valsartan/amlodipine (SPP 100/Diovan).

Role: Principal Investigator

Sponsoring Agency: Novartis

Period of Support: 3/26/06-11/21/07

Amount of Support: \$27,376

57. Project Title: Fixed Doses of Darusentan as compared to placebo in resistant hypertension (DORADO).

Role: Principal Investigator

Sponsoring Agency: Gileadco

Period of Support: 10/17/06-11/11/08

Amount of Support: \$75,780

58. Project Title: A dose blind long-term extension study to the phase 3 fixed doses of Darusentan as compared to placebo in resistant hypertension (DORADO).

Role: Principal Investigator

Sponsoring Agency: Gileadco

Period of Support: 10/17/06-indefinite

Amount of Support: \$62,970

UNIVERSITY TEACHING ROLES (Brown Medical School)

Course Title	Role	#Students Per Session	Sessions Per Year	Academic Years
Biomed 281/ Renal Pathophysiology	Small Group Leader	8-10	7-8	1993- present

HOSPITAL TEACHING ROLES (Rhode Island & Miriam Hospitals)

Course Title	Role	#Students (S) #Residents (R) #Fellows (F) Per Session	Hours Per Session	Sessions Per Year	Academic Years
--------------	------	--	----------------------	----------------------	----------------

Medical Teaching Service	Attending Physician	1-2 S 2-4 R	1	12	1993-present
Renal Consult Service	Attending Physician	1 S 1-3 R 1 F	4-8	4	1993-present
Medical Grand Rounds	Lecturer	10-15 S 10-20 R 10-20 F	1	2	1993-present
Resident Noon Conference	Lecturer	10-15 S 10-20 R	1	4	1993-present
Renal ICU Rounds	Lecturer	2-4 R 1-2 F	1	4	1996-present
Physiology Conference	Lecturer	1-2 S 1-3 R 6 F	1	2	1993-present
Hypertension Lecture, Ambulatory Block Rotation	Lecturer Medical Residency	4-8 R	3	4	1993-present

Leadership role at Renal Division conferences:

Renal Grand Rounds	Attending Physician	6 F	1	weekly	1993-present
Case Management Conference	Attending Physician	6 F	1	weekly	1993-present
Pathology Conference	Attending Physician	6 F	1	biweekly	1993-present
Journal Club	Attending Physician	6 F	1	biweekly	1993-present

Fellows Trained (Clinical and Research):

Armando Negri, MD
Michael Ullian, MD
Mayer Grosser, MD
Judith Benstein, MD
Douglas Lax, DO
Fay Oshumi, MD
Maged Taman, MD
Ajith Kumar, MD
Krupa Rajur, MD
Ahsan Mahmood, MD
Paul Shin, MD
Rujun Gong, MD, PhD
Michael Capicotto, MD
Sohail Khan, MD
Moses Kumi, MD
Kevin Lowery, MD
Premal Joshi, MD
Katherine Richman, MD

Justyna Pogodzinska, MD
Nathan Thompson, MD
Michael J. Maher, MD
Reginald Y. Gohh, MD
A. Eric Anderson, MD
Kambiz Farbaksh, MD
Elias Kanaan, MD
Kamlesh Patel, MD
Abinash Roy, MD
Elkin Estrada, MD
Martin Tran, DO
Natalie Hsu, MD
Melanie Greenan, MD
Michael Ham, MD
Clyde Mendonca, MD
Abha Saxena, MD
Chen Yu, MD, PhD
Charles Stuart, MD

Tzonko Milev, MD
Robert Dobrowolski, MD
Andrew Beaulieu, MD
Angelito Yango, MD
Abdulrahman Zanabli, MD
Racquel Rosen, MD
Joseph Weisstuch, MD
Michael Plager, MD
Ayman Wahbeh, MD
Michael Thursby, DO
Eleas J. Chafouleas, MD
Patricia Zuniga, MD
Michael Shih, MD
Gregory Warren, MD
Amit Johnsingh, MD
Subil Go, MD
Ritchie Chiu, MD

RESEARCH INTERESTS

Biophysical basis of glomerular filtration
Pathophysiology of progressive kidney failure
Determinants of compensatory kidney growth
Effects of IGF-I on glomerular structure and function
Effects of antihypertensive agents of glomerular function
Hormonal control of glomerular filtration
Role of HGF in acute and chronic renal injury